Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site

Biological Chemistry

Volumn 392, Issue 4, 2011, Pages 347-356

  Ahn, Jin Hyung ^a,b   Lee, Ho Jeong ^a   Lee, Eun Kyoung ^a   Yu, Hyun Kyung ^a   Lee, Tae Ho ^b   Yoon, Yeup ^a   Kim, Sun Jin ^c   Kim, Jang Seong ^a  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis inhibitors; Apolipoprotein(a); Fibrinolysis; Kringles; Lysine binding site; Site directed mutagenesis

Indexed keywords

ANGIOSTATIN; APOLIPOPROTEIN A; LYSINE; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; KRINGLE DOMAIN; MUTATION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANGIOSTATINS; APOLIPOPROTEINS A; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; KRINGLES; LYSINE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79955415249     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2011.023     Document Type: Article

References (49)

1. Ahn, J.H., Kim, J.S., Yu, H.K., Lee, H.J., and Yoon, Y. (2004). A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway. J. Biol. Chem. 279, 21808-21814. (Pubitemid 38679369)
2. Aisina, R.B., Mukhametova, L.I., Gulin, D.A., Levashov, M.Y., Prisyazhnaya, N.V., Gershkovich, K.B., and Varfolomeyev, S.D. (2009). Inhibitory effect of angiostatins on activity of the plasminogen/ plasminogen activator system. Biochemistry (Moscow) 74, 1104-1113.
3. Beerepoot, L.V., Witteveen, E.O., Groenewegen, G., Fogler, W.E., Sim, B.K., Sidor, C., Zonnenberg, B.A., Schramel, F., Gebbink, M.F., and Voest, E.E. (2003). Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: A pharmacokinetic and long-term safety study. Clin. Cancer Res. 9, 4025-4033. (Pubitemid 37204017)
4. Blom, J.W., Doggen, C.J., Osanto, S., and Rosendaal, F.R. (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J. Am. Med. Assoc. 293, 715-722. (Pubitemid 40216041)
5. Boffa, M.B., Marcovina, S.M., and Koschinsky, M.L. (2004). Lipoprotein( a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin. Biochem. 37, 333-343. (Pubitemid 38490450)
6. Callow, M.J. and Rubin, E.M. (1995). Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. J. Biol. Chem. 270, 23914-23917.
7. Cao, Y., Cao, R., and Veitonmaki, N. (2002). Kringle structures and antiangiogenesis. Curr. Med. Chem. Anticancer Agents 2, 667-681. (Pubitemid 35175266)
8. Carmeliet, P. and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
9. Doll, J.A. and Soff, G.A. (2005). Angiostatin. Cancer Treat. Res. 126, 175-204.
10. Ernst, A., Helmhold, M., Brunner, C., Petho-Schramm, A., Armstrong, V.W., and Muller, H.J. (1995). Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J. Biol. Chem. 270, 6227-6234.
11. Fless, G.M., ZumMallen, M.E., and Scanu, A.M. (1986). Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J. Biol. Chem. 261, 8712-8718. (Pubitemid 17205067)
12. Fleury, V. and Angles-Cano, E. (1991). Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines. Biochemistry 30, 7630-7638.
13. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
14. Folkman, J. (1995a). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
15. Folkman, J. (1995b). The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res. Treat. 36, 109-118.
16. Gabel, B.R., May, L.F., Marcovina, S.M., and Koschinsky, M.L. (1996). Lipoprotein(a) assembly. Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler. Thromb. Vasc. Biol. 16, 1559-1567. (Pubitemid 26427611)
17. Guevara, J., Jr., Knapp, R.D., Honda, S., Northup, S.R., and Morrisett, J.D. (1992). A structural assessment of the apowax protein of human lipoproteinwax. Proteins 12, 188-199.
18. Hancock, M.A., Boffa, M.B., Marcovina, S.M., Nesheim, M.E., and Koschinsky, M.L. (2003). Inhibition of plasminogen activation by lipoprotein(a): Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278, 23260-23269. (Pubitemid 36830139)
19. Harpel, P.C., Gordon, B.R., and Parker, T.S. (1989). Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA 86, 3847-3851. (Pubitemid 19141842)
20. Heymach, J.V., Desai, J., Manola, J., Davis, D.W., McConkey, D.J., Harmon, D., Ryan, D.P., Goss, G., Quigley, T., Van den Abbeele, A.D., et al. (2004). Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 10, 5732-5740. (Pubitemid 39180949)
21. Hoover, G.J., Menhart, N., Martin, A., Warder, S., and Castellino, F.J. (1993). Amino acids of the recombinant kringle 1 domain of human plasminogen that stabilize its interaction with omegaamino acids. Biochemistry 32, 10936-10943. (Pubitemid 23331999)
22. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342. (Pubitemid 38702844)
23. Kang, K.Y., Park, J.H., Lim, I.H., Kim, S.G., Park, S.H., Kim,W.K., Hong, J.W., You, H.K., Jung, K.H., and Kim, C.W. (2006). Crystallization of antiangiogenic Kringle V derived from human apolipoprotein A: Crystallization applied to purification and formulation. Biosci. Biotechnol. Biochem. 70, 916-925.
24. Kikuchi, Y., Kizawa, I., Oomori, K., Matsuda, M., and Kato, K. (1986). Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites. Acta Obstet. Gynecol. Scand. 65, 453-456. (Pubitemid 16015184)
25. Kim, J.S., Chang, J.H., Yu, H.K., Ahn, J.H., Yum, J.S., Lee, S.K., Jung, K.H., Park, D.H., Yoon, Y., Byun, S.M., et al. (2003). Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein( a). J. Biol. Chem. 278, 29000-29008. (Pubitemid 36935812)
26. Kim, J.S., Yu, H.K., Ahn, J.H., Lee, H.J., Hong, S.W., Jung, K.H., Chang, S.I., Hong, Y.K., Joe, Y.A., Byun, S.M., et al. (2004). Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem. Biophys. Res. Commun. 313, 534-540.
27. Kraft, H.G., Haibach, C., Lingenhel, A., Brunner, C., Trommsdorff, M., Kronenberg, F., Muller, H.J., and Utermann, G. (1995). Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism. Hum. Genet. 95, 275-282.
28. Kraft, H.G., Lingenhel, A., Pang, R.W., Delport, R., Trommsdorff, M., Vermaak, H., Janus, E.D., and Utermann, G. (1996). Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: The distribution of null alleles is non-random. Eur. J. Hum. Genet. 4, 74-87.
29. Kuenen, B.C., Rosen, L., Smit, E.F., Parson, M.R., Levi, M., Ruijter, R., Huisman, H., Kedde, M.A., Noordhuis, P., van der Vijgh, W.J., et al. (2002). Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667. (Pubitemid 34260548)
30. Kwaan, H.C. and McMahon, B. (2009). The role of plasminogenplasmin system in cancer. Cancer Treat. Res. 148, 43-66.
31. Lee, T.H., Kim, M.D., Shin, S.Y., Lim, H.K., and Seo, J.H. (2006). Disruption of hexokinase II (HXK2) partly relieves glucose repression to enhance production of human kringle fragment in gratuitous recombinant Saccharomyces cerevisiae. J. Biotechnol. 126, 562-567.
32. Marcovina, S.M. and Koschinsky, M.L. (2003). Evaluation of lipoprotein( a) as a prothrombotic factor: Progress from bench to bedside. Curr. Opin. Lipidol. 14, 361-366. (Pubitemid 36951901)
33. McLean, J.W., Tomlinson, J.E., Kuang, W.J., Eaton, D.L., Chen, E.Y., Fless, G.M., Scanu, A.M., and Lawn, R.M. (1987). cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132-137. (Pubitemid 17158542)
34. Mulichak, A.M., Tulinsky, A., and Ravichandran, K.G. (1991). Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-Å resolution. Biochemistry 30, 10576-10588.
35. Nielsen, P.R., Einer-Jensen, K., Holtet, T.L., Andersen, B.D., Poulsen, F.M., and Thogersen, H.C. (1993). Protein-ligand interactions in the lysine-binding site of plasminogen kringle 4 are different in crystal and solution. Electrostatic interactions studied by site-directed mutagenesis exclude Lys35 as an important acceptor in solution. Biochemistry 32, 13019-13025. (Pubitemid 24005907)
36. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328. (Pubitemid 24324921)
37. Patthy, L., Trexler, M., Vali, Z., Banyai, L., and Varadi, A. (1984). Kringles: Modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structures of proteases. FEBS Lett. 171, 131-136. (Pubitemid 14122475)
38. ™Thr substitution in Kringle IV type 10 of apolipoprotein(a). Thromb. Res. 90, 125-130. (Pubitemid 28343529)
39. Rahman, M.N., Petrounevitch, V., Jia, Z., and Koschinsky, M.L. (2001). Antifibrinolytic effect of single apo(a) kringle domains: Relationship to fibrinogen binding. Protein Eng. 14, 427-438. (Pubitemid 32762380)
40. Rejante, M.R., Byeon, I.J., and Llinas, M. (1991). Ligand specificity of human plasminogen kringle 4. Biochemistry 30, 11081-11092.
41. Rickles, F.R. (2006). Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 35, 103-110.
42. Rouy, D., Grailhe, P., Nigon, F., Chapman, J., and Angles-Cano, E. (1991). Lipoprotein(a) impairs generation of plasmin by fibrinbound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler. Thromb. 11, 629-638.
43. Sangrar, W., Gabel, B.R., Boffa, M.B., Walker, J.B., Hancock, M.A., Marcovina, S.M., Horrevoets, A.J., Nesheim, M.E., and Koschinsky, M.L. (1997). The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 36, 10353-10363. (Pubitemid 27374127)
44. Scanu, A.M. and Edelstein, C. (1995). Kringle-dependent structural and functional polymorphism of apolipoprotein (a). Biochim. Biophys. Acta 1256, 1-12.
45. Stack, M.S., Gately, S., Bafetti, L.M., Enghild, J.J., and Soff, G.A. (1999). Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 340, 77-84. (Pubitemid 29251093)
46. Sugiyama, N., Iwamoto, M., and Abiko, Y. (1987). Effects of kringles derived from human plasminogen on fibrinolysis in vitro. Thromb. Res. 47, 459-468. (Pubitemid 17148060)
47. Tsurupa, G., Yakovlev, S., Pechik, I., Lamanuzzi, L.B., Angles- Cano, E., and Medved, L. (2006). Interaction of fibrin(ogen) with apolipoprotein(a): Further characterization and identification of a novel lysine-dependent apolipoprotein(a)-binding site within the g chain 287-411 region. Biochemistry 45, 10624-10632. (Pubitemid 44320477)
48. Tuszynski, G.P., Sharma, M.R., Rothman, V.L., and Sharma, M.C. (2002). Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc. Res. 64, 448-462. (Pubitemid 35370746)
49. Verheul, H.M., Jorna, A.S., Hoekman, K., Broxterman, H.J., Gebbink, M.F., and Pinedo, H.M. (2000). Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96, 4216-4221.